UA80822C2 - Oily solution for injection comprising ester of progesteron and androgen ester - Google Patents

Oily solution for injection comprising ester of progesteron and androgen ester Download PDF

Info

Publication number: UA80822C2
Authority: UA; Ukraine
Prior art keywords: etonogestrel; injection; ester; undecanoate; needle
Prior art date: 2002-05-30

Application number

UA20041109509A

Other languages

English (en)

Ukrainian (uk)

Inventor

Dirk Leysen

Original Assignee

Organon Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-30

Filing date

2003-05-23

Publication date

2007-11-12

2003-05-23 Application filed by Organon Nv filed Critical Organon Nv

2007-11-12 Publication of UA80822C2 publication Critical patent/UA80822C2/uk

Links

238000002347 injection Methods 0.000 title claims abstract description 52
239000007924 injection Substances 0.000 title claims abstract description 52
239000000243 solution Substances 0.000 title claims abstract description 49
239000003098 androgen Substances 0.000 title claims abstract description 18
150000002148 esters Chemical class 0.000 title claims description 25
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title 2
239000000583 progesterone congener Substances 0.000 claims abstract description 28
229960002941 etonogestrel Drugs 0.000 claims description 88
GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 claims description 87
-1 solinestrenol Chemical compound 0.000 claims description 20
IAFQYUQIAOWKSB-UHFFFAOYSA-N Ethyl undecanoate Chemical compound CCCCCCCCCCC(=O)OCC IAFQYUQIAOWKSB-UHFFFAOYSA-N 0.000 claims description 13
238000010254 subcutaneous injection Methods 0.000 claims description 5
239000007929 subcutaneous injection Substances 0.000 claims description 5
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 3
229960004400 levonorgestrel Drugs 0.000 claims description 3
ATXHVCQZZJYMCF-XUDSTZEESA-N Allylestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)CC=C)[C@@H]4[C@@H]3CCC2=C1 ATXHVCQZZJYMCF-XUDSTZEESA-N 0.000 claims description 2
LVHOURKCKUYIGK-RGUJTQARSA-N Dimethisterone Chemical compound C1([C@@H](C)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C#CC)(O)[C@@]2(C)CC1 LVHOURKCKUYIGK-RGUJTQARSA-N 0.000 claims description 2
ICTXHFFSOAJUMG-SLHNCBLASA-N Norethynodrel Chemical compound C1CC(=O)CC2=C1[C@H]1CC[C@](C)([C@](CC3)(O)C#C)[C@@H]3[C@@H]1CC2 ICTXHFFSOAJUMG-SLHNCBLASA-N 0.000 claims description 2
229960002692 allylestrenol Drugs 0.000 claims description 2
229960004976 desogestrel Drugs 0.000 claims description 2
RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims description 2
AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 claims description 2
229960003309 dienogest Drugs 0.000 claims description 2
229950006690 dimethisterone Drugs 0.000 claims description 2
229960000445 ethisterone Drugs 0.000 claims description 2
CHNXZKVNWQUJIB-CEGNMAFCSA-N ethisterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 CHNXZKVNWQUJIB-CEGNMAFCSA-N 0.000 claims description 2
229960000218 etynodiol Drugs 0.000 claims description 2
SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 claims description 2
229960005352 gestodene Drugs 0.000 claims description 2
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 2
229960002831 norgestrienone Drugs 0.000 claims description 2
GVDMJXQHPUYPHP-FYQPLNBISA-N norgestrienone Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)C#C)C=C3)C3=C21 GVDMJXQHPUYPHP-FYQPLNBISA-N 0.000 claims description 2
ONKUMRGIYFNPJW-KIEAKMPYSA-N ethynodiol diacetate Chemical compound C1C[C@]2(C)[C@@](C#C)(OC(C)=O)CC[C@H]2[C@@H]2CCC3=C[C@@H](OC(=O)C)CC[C@@H]3[C@H]21 ONKUMRGIYFNPJW-KIEAKMPYSA-N 0.000 claims 1
NPAGDVCDWIYMMC-IZPLOLCNSA-N nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 claims 1
229960004719 nandrolone Drugs 0.000 claims 1
229940053934 norethindrone Drugs 0.000 claims 1
238000007920 subcutaneous administration Methods 0.000 abstract description 14
239000008194 pharmaceutical composition Substances 0.000 abstract description 7
YSGQGNQWBLYHPE-CFUSNLFHSA-N (7r,8r,9s,10r,13s,14s,17s)-17-hydroxy-7,13-dimethyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 YSGQGNQWBLYHPE-CFUSNLFHSA-N 0.000 description 46
ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 32
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 29
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 27
239000000312 peanut oil Substances 0.000 description 23
235000019483 Peanut oil Nutrition 0.000 description 22
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 21
238000007918 intramuscular administration Methods 0.000 description 18
241000283973 Oryctolagus cuniculus Species 0.000 description 17
239000003921 oil Substances 0.000 description 17
235000019198 oils Nutrition 0.000 description 17
239000002904 solvent Substances 0.000 description 16
229960002903 benzyl benzoate Drugs 0.000 description 14
229960003604 testosterone Drugs 0.000 description 14
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 12
102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 12
206010024769 Local reaction Diseases 0.000 description 11
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
229960000746 testosterone undecanoate Drugs 0.000 description 9
208000002193 Pain Diseases 0.000 description 8
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 8
230000000694 effects Effects 0.000 description 8
FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 8
VOCBWIIFXDYGNZ-IXKNJLPQSA-N testosterone enanthate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC2 VOCBWIIFXDYGNZ-IXKNJLPQSA-N 0.000 description 8
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 7
238000002657 hormone replacement therapy Methods 0.000 description 7
229960003484 testosterone enanthate Drugs 0.000 description 7
UDSFVOAUHKGBEK-CNQKSJKFSA-N testosterone undecanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCCC)[C@@]1(C)CC2 UDSFVOAUHKGBEK-CNQKSJKFSA-N 0.000 description 7
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
229940011871 estrogen Drugs 0.000 description 6
239000000262 estrogen Substances 0.000 description 6
238000000034 method Methods 0.000 description 6
230000035515 penetration Effects 0.000 description 6
229940071643 prefilled syringe Drugs 0.000 description 6
150000003509 tertiary alcohols Chemical class 0.000 description 6
150000001875 compounds Chemical class 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
238000005160 1H NMR spectroscopy Methods 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
235000019445 benzyl alcohol Nutrition 0.000 description 4
239000003433 contraceptive agent Substances 0.000 description 4
RGXWDWUGBIJHDO-UHFFFAOYSA-N ethyl decanoate Chemical compound CCCCCCCCCC(=O)OCC RGXWDWUGBIJHDO-UHFFFAOYSA-N 0.000 description 4
238000010255 intramuscular injection Methods 0.000 description 4
239000007927 intramuscular injection Substances 0.000 description 4
230000007774 longterm Effects 0.000 description 4
WQEPLUUGTLDZJY-UHFFFAOYSA-M pentadecanoate Chemical compound CCCCCCCCCCCCCCC([O-])=O WQEPLUUGTLDZJY-UHFFFAOYSA-M 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
230000035807 sensation Effects 0.000 description 4
239000000126 substance Substances 0.000 description 4
SZHOJFHSIKHZHA-UHFFFAOYSA-N tridecanoic acid Chemical compound CCCCCCCCCCCCC(O)=O SZHOJFHSIKHZHA-UHFFFAOYSA-N 0.000 description 4
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000002411 adverse Effects 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
229940124558 contraceptive agent Drugs 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
239000000203 mixture Substances 0.000 description 3
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
230000021595 spermatogenesis Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
208000001333 Colorectal Neoplasms Diseases 0.000 description 2
102000012673 Follicle Stimulating Hormone Human genes 0.000 description 2
108010079345 Follicle Stimulating Hormone Proteins 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
WAHQVRCNDCHDIB-QZYSPNBYSA-N [(3s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-acetyloxy-6,10,13-trimethyl-1,2,3,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-yl] 3-cyclopentylpropanoate Chemical compound O([C@@H]1C=C2C(C)=C[C@H]3[C@@H]4CC[C@]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)(OC(=O)C)C(C)=O)C(=O)CCC1CCCC1 WAHQVRCNDCHDIB-QZYSPNBYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000012267 brine Substances 0.000 description 2
229960004424 carbon dioxide Drugs 0.000 description 2
235000011089 carbon dioxide Nutrition 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
229940028334 follicle stimulating hormone Drugs 0.000 description 2
229940102223 injectable solution Drugs 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000002583 male contraceptive agent Substances 0.000 description 2
DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
LBCZOTMMGHGTPH-UHFFFAOYSA-N 2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCO)C=C1 LBCZOTMMGHGTPH-UHFFFAOYSA-N 0.000 description 1
QGLVWTFUWVTDEQ-UHFFFAOYSA-N 2-chloro-3-methoxyphenol Chemical compound COC1=CC=CC(O)=C1Cl QGLVWTFUWVTDEQ-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
208000034656 Contusions Diseases 0.000 description 1
241000238557 Decapoda Species 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
208000033830 Hot Flashes Diseases 0.000 description 1
206010060800 Hot flush Diseases 0.000 description 1
206010021639 Incontinence Diseases 0.000 description 1
206010022086 Injection site pain Diseases 0.000 description 1
YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 description 1
206010030247 Oestrogen deficiency Diseases 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
102000004451 Pituitary Gonadotropins Human genes 0.000 description 1
108010081865 Pituitary Gonadotropins Proteins 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
206010039509 Scab Diseases 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
206010042674 Swelling Diseases 0.000 description 1
206010047791 Vulvovaginal dryness Diseases 0.000 description 1
ODZDZTOROXGJAV-IRWJKHRASA-N [(8r,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 4-butylcyclohexane-1-carboxylate Chemical compound C1CC(CCCC)CCC1C(=O)O[C@@H]1[C@@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4CC[C@H]3[C@@H]2CC1 ODZDZTOROXGJAV-IRWJKHRASA-N 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
239000002199 base oil Substances 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
210000003756 cervix mucus Anatomy 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
208000029078 coronary artery disease Diseases 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
210000004696 endometrium Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
BWEZMBMJQRHPSZ-UHFFFAOYSA-N ethyl undecanoate Chemical compound CCCCCCCCCCC(=O)OCC.CCCCCCCCCCC(=O)OCC BWEZMBMJQRHPSZ-UHFFFAOYSA-N 0.000 description 1
JYILPERKVHXLNF-QMNUTNMBSA-N ethynodiol Chemical compound O[C@H]1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 JYILPERKVHXLNF-QMNUTNMBSA-N 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000002513 implantation Methods 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
230000007803 itching Effects 0.000 description 1
238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
229940040129 luteinizing hormone Drugs 0.000 description 1
229960001910 lynestrenol Drugs 0.000 description 1
230000009245 menopause Effects 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
235000021313 oleic acid Nutrition 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
229940127234 oral contraceptive Drugs 0.000 description 1
239000003539 oral contraceptive agent Substances 0.000 description 1
230000016087 ovulation Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000012071 phase Substances 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
230000009933 reproductive health Effects 0.000 description 1
230000006965 reversible inhibition Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
150000003515 testosterones Chemical class 0.000 description 1
230000005919 time-dependent effect Effects 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Reproductive Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Infusion, Injection, And Reservoir Apparatuses (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Orthopedics, Nursing, And Contraception (AREA)

UA20041109509A 2002-05-30 2003-05-23 Oily solution for injection comprising ester of progesteron and androgen ester UA80822C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02077126		2002-05-30
PCT/EP2003/050192 WO2003101539A1 (en)	2002-05-30	2003-05-23	Self-administered contraceptive injection of oily solution

Publications (1)

Publication Number	Publication Date
UA80822C2 true UA80822C2 (en)	2007-11-12

Family

ID=29595016

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20041109509A UA80822C2 (en)	2002-05-30	2003-05-23	Oily solution for injection comprising ester of progesteron and androgen ester

Country Status (23)

Country	Link
US (1)	US20060094698A1 (es)
EP (1)	EP1513587A1 (es)
JP (1)	JP2005533036A (es)
KR (1)	KR20050010014A (es)
CN (1)	CN1298330C (es)
AR (1)	AR040131A1 (es)
AU (1)	AU2003238084A1 (es)
BR (1)	BR0311423A (es)
CA (1)	CA2487639A1 (es)
HR (1)	HRP20041126A2 (es)
IL (1)	IL165204A0 (es)
IS (1)	IS7539A (es)
MX (1)	MXPA04011928A (es)
NO (1)	NO20044976L (es)
NZ (1)	NZ536735A (es)
PE (1)	PE20040676A1 (es)
PL (1)	PL373074A1 (es)
RS (1)	RS100904A (es)
RU (1)	RU2328289C2 (es)
TW (1)	TW200404552A (es)
UA (1)	UA80822C2 (es)
WO (1)	WO2003101539A1 (es)
ZA (1)	ZA200409646B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200727920A (en) *	2005-06-21	2007-08-01	Organon Nv	New regimens for oral monophasic contraceptives
EP4186545A1 (en)	2012-04-06	2023-05-31	Antares Pharma, Inc.	Needle assisted jet injection administration of testosterone compositions
WO2014093818A2 (en) *	2012-12-14	2014-06-19	Bioject, Inc.	Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
DK3659647T3 (da) *	2013-02-11	2024-04-22	Antares Pharma Inc	Nålestøttet jetinjektionsindretning med reduceret udløserkraft
CN105744983B (zh) *	2013-08-12	2019-12-27	纳米医学系统公司	用于缓释在增溶剂中的低水溶性治疗剂的装置和方法
WO2020180942A1 (en) *	2019-03-06	2020-09-10	Propella Therapeutics, Inc.	Abiraterone prodrugs
CN111057120B (zh) *	2019-12-27	2021-04-27	苏州翔实医药发展有限公司	一种依托孕烯衍生物a及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2970153A (en) *	1959-07-27	1961-01-31	Leo Ab	Alkoxyphenyl-propionyl esters of 17alpha-hydroxyprogesterone
DE3836862A1 (de) *	1988-10-27	1990-05-03	Schering Ag	Mittel zur transdermalen applikation von steroidhormonen
CN1102095A (zh) *	1993-10-30	1995-05-03	浙江医科大学	长效雄激素类制剂——十一酸睾丸注射液
HUT75159A (en) *	1993-12-27	1997-04-28	Akzo Nobel Nv	Percutaneously absorbable preparation, containing 3-ketodesogestrel and 17 beta-estradiol
US5599302A (en) *	1995-01-09	1997-02-04	Medi-Ject Corporation	Medical injection system and method, gas spring thereof and launching device using gas spring
JPH11509222A (ja) *	1995-07-17	1999-08-17	シェリングアクチェンゲゼルシャフト	１３−エチル−１７β−ヒドロキシ−１１−メチレン−１８，１９−ジノル−１７α−プレグン−４−エン−２０−イン−３−オンのエステルを含む経皮投与のための剤
WO1999067270A1 (en) *	1998-06-19	1999-12-29	Akzo Nobel N.V.	Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
SK282796B6 (sk) *	1998-06-19	2002-12-03	Akzo Nobel N.V.	Testosterónový derivát, farmaceutický prostriedok s jeho obsahom, jeho použitie a súprava s jeho obsahom
GB0000313D0 (en) *	2000-01-10	2000-03-01	Astrazeneca Uk Ltd	Formulation
PT1267885E (pt) *	2000-02-15	2007-05-31	Schering Ag	Formulação contraceptiva masculina compreendendo noretisterona
DK1313511T3 (da) *	2000-08-23	2006-03-20	Akzo Nobel Nv	Testosteronesterformulering til human brug

2003
- 2003-05-19 TW TW092113496A patent/TW200404552A/zh unknown
- 2003-05-23 CA CA002487639A patent/CA2487639A1/en not_active Abandoned
- 2003-05-23 BR BR0311423-6A patent/BR0311423A/pt not_active IP Right Cessation
- 2003-05-23 WO PCT/EP2003/050192 patent/WO2003101539A1/en not_active Ceased
- 2003-05-23 RU RU2004138811/15A patent/RU2328289C2/ru not_active IP Right Cessation
- 2003-05-23 EP EP03735716A patent/EP1513587A1/en not_active Withdrawn
- 2003-05-23 MX MXPA04011928A patent/MXPA04011928A/es not_active Application Discontinuation
- 2003-05-23 JP JP2004508891A patent/JP2005533036A/ja active Pending
- 2003-05-23 AU AU2003238084A patent/AU2003238084A1/en not_active Abandoned
- 2003-05-23 UA UA20041109509A patent/UA80822C2/uk unknown
- 2003-05-23 US US10/515,714 patent/US20060094698A1/en not_active Abandoned
- 2003-05-23 HR HR20041126A patent/HRP20041126A2/hr not_active Application Discontinuation
- 2003-05-23 KR KR10-2004-7019341A patent/KR20050010014A/ko not_active Withdrawn
- 2003-05-23 CN CNB038123622A patent/CN1298330C/zh not_active Expired - Fee Related
- 2003-05-23 RS YU100904A patent/RS100904A/sr unknown
- 2003-05-23 PL PL03373074A patent/PL373074A1/xx not_active Application Discontinuation
- 2003-05-23 NZ NZ536735A patent/NZ536735A/en unknown
- 2003-05-28 AR ARP030101860A patent/AR040131A1/es unknown
- 2003-05-29 PE PE2003000522A patent/PE20040676A1/es not_active IP Right Cessation
2004
- 2004-11-14 IL IL16520404A patent/IL165204A0/xx unknown
- 2004-11-16 NO NO20044976A patent/NO20044976L/no unknown
- 2004-11-18 IS IS7539A patent/IS7539A/is unknown
- 2004-11-29 ZA ZA200409646A patent/ZA200409646B/en unknown

Also Published As

Publication number	Publication date
PL373074A1 (en)	2005-08-08
BR0311423A (pt)	2005-03-15
EP1513587A1 (en)	2005-03-16
RS100904A (sr)	2006-10-27
WO2003101539A1 (en)	2003-12-11
NO20044976L (no)	2004-12-23
AU2003238084A1 (en)	2003-12-19
KR20050010014A (ko)	2005-01-26
PE20040676A1 (es)	2004-09-25
JP2005533036A (ja)	2005-11-04
US20060094698A1 (en)	2006-05-04
AR040131A1 (es)	2005-03-16
RU2004138811A (ru)	2005-06-10
CN1655847A (zh)	2005-08-17
ZA200409646B (en)	2006-06-28
IS7539A (is)	2004-11-18
CN1298330C (zh)	2007-02-07
HRP20041126A2 (en)	2005-04-30
RU2328289C2 (ru)	2008-07-10
MXPA04011928A (es)	2005-03-31
TW200404552A (en)	2004-04-01
IL165204A0 (en)	2005-12-18
CA2487639A1 (en)	2003-12-11
NZ536735A (en)	2007-01-26

Publication	Publication Date	Title
RU2325910C2 (ru)	2008-06-10	Новые сложные эфиры этоногестрела
MX2012006755A (es)	2012-11-23	Gel transdermico de progestina/estradiol.
UA80822C2 (en)	2007-11-12	Oily solution for injection comprising ester of progesteron and androgen ester
RU2322986C2 (ru)	2008-04-27	Применение новых сложных эфиров этоногестрела
Goldzieher	1993	The history of steroidal contraceptive development: the estrogens
DE2218831A1 (de)	1973-10-31	Methode zur kontrazeption durch verabfolgung von stufenkombinationspraeparaten
HK1072568B (en)	2008-07-18	Use of new etonogestrel esters
Sitruk-Ware et al.	1984	Percutaneous oestrogen therapy
BRAMBILLA et al.	1961	Experiences with the Use of Polyestradiol Phosphate, a Long-acting Estrogen